ClinicalTrials.gg
CompletedNCT07349459Updated Oct 26, 2026

Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

An interventional study of Group 1 (Doxorubicin group) and Group 2: Vitamin D group in Melatonin, Breast Cancer Patients Diagnosed and Vitamin D Concentration, sponsored by Tanta University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Tanta University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Apr 2025, registered Jan 2026).
Updated Oct 21, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing Vitamin D in Breast Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Vitamin D · Breast Neoplasms.

Enrollment
7th of 18
90 · median 64
Started
2025
the only one that year
No phase
4 of 18
none open now
Registered
18th of 18
by date

Among the 18 studies testing Vitamin D in Breast Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2025, is one of 4 with no phase, and was the 18th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 18 studies testing Vitamin D in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Vitamin D

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Vitamin D in Breast Neoplasms, or all of them as a file.
02

Study summary

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Read the detailed description

Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.

Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .

Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .

To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .

Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .

Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .

Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

03

Conditions studied

  • Melatonin
  • Breast Cancer Patients Diagnosed
  • Vitamin D Concentration
  • Doxorubicin

Browse trials for

Keywords

  • Vitamin D
  • Doxorubicin
  • Cardioprotective Effect
  • Melatonin
  • Breast Cancer Patients
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 18 to 65 years old.
  • Gender: female.
  • Positive breast cancer women who are scheduled to receive Doxorubicin.
  • Have a good performance status according to the with a score of 0-2.
  • Normal baseline Echocardiography with ≥ 50%.
  • Normal renal and liver function tests.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Women with positive of breast cancer.
  • Formerly treated with Doxorubicin.
  • Patients with a known to any of the used drugs.
  • On other concomitant vitamins or food supplements.
  • Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
  • Impaired Left ventricular systolic function in which the \< 50%.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Group 1 (Doxorubicin group)

    30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

    Drug: Group 1 (Doxorubicin group)

  • Experimental
    Group 2 (Vitamin D group)

    patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks

    Drug: Group 2: Vitamin D group

  • Experimental
    Group 3 (melatonin group)

    30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks.

    Drug: Group 3: melatonin group

Interventions

  • DrugDoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

  • DrugVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks

  • DrugMelatoninStudies of MelatoninMelatonin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks

06

What researchers measure

Primary outcomes

  1. Decreasing incidence and severity of cardiotoxicity

    Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Plasma B-Type Natriuretic Peptide (BNP) Concentration

    Change in plasma B-type natriuretic peptide (BNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL.

    Time frame: Baseline and 12 weeks.

  2. Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration

    Change in serum/plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 12 weeks, measured using a chemiluminescent microparticle immunoassay (CMIA) on the Abbott Alinity i analyzer. Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in pg/mL.

    Time frame: Baseline and 12 weeks.

  3. Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Concentration

    Change in serum/plasma high-sensitivity cardiac troponin I (hs-cTnI) concentration from baseline to 12 weeks, measured using the Alinity i STAT High Sensitive Troponin-I chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L.

    Time frame: Baseline and 12 weeks.

  4. Change in Myeloperoxidase (MPO) Concentration

    Change in myeloperoxidase (MPO) concentration from baseline to 12 weeks, measured using a human MPO double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL.

    Time frame: Baseline and 12 weeks.

  5. Change in Interleukin-6 (IL-6) Concentration

    Change in interleukin-6 (IL-6) concentration from baseline to 12 weeks, measured using a human IL-6 double-antibody sandwich enzyme-linked immunosorbent assay (ELISA; SunRed Biological Technology Co., Ltd.). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/L.

    Time frame: Baseline and 12 weeks.

  6. Change in Creatine Kinase-MB (CK-MB) Concentration

    Change in serum/plasma creatine kinase-MB (CK-MB) concentration from baseline to 12 weeks, measured using the Alinity i STAT CK-MB chemiluminescent microparticle immunoassay (CMIA). Changes will be calculated as the 12-week concentration minus the baseline concentration and expressed in ng/mL.

    Time frame: Baseline and 12 weeks.

07

Study locations

1 site
  • Tanta University
    Tanta, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — All data will be available when needed

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in May 2026, 13 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 13 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Apr 2026 → Apr 2025, primary completion Aug 2026 → May 2026 and completion Aug 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Apr 1, 2025was Apr 2026
Primary completionActual
May 30, 2026was Aug 2026
CompletionActual
May 30, 2026was Aug 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 6, 2026
Start date
Apr 30, 2026→Apr 1, 2025
Oct 21, 2026
Primary completion
Aug 30, 2026→May 30, 2026
Oct 21, 2026
Study completion
Aug 30, 2026→May 30, 2026
Oct 21, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 21, 2026
  • Editedchange in the serum level of the (biological markers)and cardiacmarkers.Time frame: 12 weeks
What changed on Oct 26, 2026
  • AddedChange in Plasma B-Type Natriuretic Peptide (BNP) ConcentrationTime frame: Baseline and 12 weeks.
  • AddedChange in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) ConcentrationTime frame: Baseline and 12 weeks.
  • AddedChange in High-Sensitivity Cardiac Troponin I (hs-cTnI) ConcentrationTime frame: Baseline and 12 weeks.
  • AddedChange in Myeloperoxidase (MPO) ConcentrationTime frame: Baseline and 12 weeks.
  • AddedChange in Interleukin-6 (IL-6) ConcentrationTime frame: Baseline and 12 weeks.
  • AddedChange in Creatine Kinase-MB (CK-MB) ConcentrationTime frame: Baseline and 12 weeks.
  • Removedchange in the serum level of biological and cardiacmarkers.Time frame: 12 weeks
across 2 updates, Oct 21, 2026 – Oct 26, 2026
Show all 3 updates
  1. Oct 26, 2026
    Secondary outcomes 6 added, 1 removed
    What changed in the outcomes
    • AddedChange in Plasma B-Type Natriuretic Peptide (BNP) ConcentrationTime frame: Baseline and 12 weeks.
    • AddedChange in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) ConcentrationTime frame: Baseline and 12 weeks.
    • AddedChange in High-Sensitivity Cardiac Troponin I (hs-cTnI) ConcentrationTime frame: Baseline and 12 weeks.
    • AddedChange in Myeloperoxidase (MPO) ConcentrationTime frame: Baseline and 12 weeks.
    • AddedChange in Interleukin-6 (IL-6) ConcentrationTime frame: Baseline and 12 weeks.
    • AddedChange in Creatine Kinase-MB (CK-MB) ConcentrationTime frame: Baseline and 12 weeks.
    • Removedchange in the serum level of biological and cardiacmarkers.Time frame: 12 weeks
  2. Oct 21, 2026
    Start date Apr 30, 2026→Apr 1, 2025
    Primary completion Aug 30, 2026→May 30, 2026
    Study completion Aug 30, 2026→May 30, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Editedchange in the serum level of the (biological markers)and cardiacmarkers.Time frame: 12 weeks
    + 3 other changes: verification date, design details and arm descriptions
  3. Oct 6, 2026
    Not yet recruiting→Completed
    + 2 other changes: date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07349459
Lead sponsor
Tanta University
Responsible party
Majed Essa Alharbi (Resident, Tanta University) — Principal investigator
First posted
Jan 16, 2026
Start date
Apr 1, 2025
Primary completion
May 30, 2026
Completion
May 30, 2026
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vitamin D · Melatonin

Start the discussion